BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 28446646)

  • 1. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study.
    Fernandez HH; Factor SA; Hauser RA; Jimenez-Shahed J; Ondo WG; Jarskog LF; Meltzer HY; Woods SW; Bega D; LeDoux MS; Shprecher DR; Davis C; Davis MD; Stamler D; Anderson KE
    Neurology; 2017 May; 88(21):2003-2010. PubMed ID: 28446646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Anderson KE; Stamler D; Davis MD; Factor SA; Hauser RA; Isojärvi J; Jarskog LF; Jimenez-Shahed J; Kumar R; McEvoy JP; Ochudlo S; Ondo WG; Fernandez HH
    Lancet Psychiatry; 2017 Aug; 4(8):595-604. PubMed ID: 28668671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 29024264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia.
    Fernandez HH; Stamler D; Davis MD; Factor SA; Hauser RA; Jimenez-Shahed J; Ondo WG; Jarskog LF; Woods SW; Bega D; LeDoux MS; Shprecher DR; Anderson KE
    J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1317-1323. PubMed ID: 31296586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazine.
    Hauser RA; Barkay H; Wilhelm A; Wieman M; Savola JM; Gordon MF
    Parkinsonism Relat Disord; 2022 Apr; 97():47-51. PubMed ID: 35299070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive Dyskinesia.
    Sajatovic M; Finkbeiner S; Wilhelm A; Barkay H; Chaijale N; Gross N; Gordon MF
    Am J Geriatr Psychiatry; 2022 Mar; 30(3):360-371. PubMed ID: 34511333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.
    Solmi M; Pigato G; Kane JM; Correll CU
    Drug Des Devel Ther; 2018; 12():1215-1238. PubMed ID: 29795977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder.
    McIntyre RS; Calabrese JR; Nierenberg AA; Farahmand K; Yonan C; Siegert S; Burke J
    J Affect Disord; 2019 Mar; 246():217-223. PubMed ID: 30583148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
    Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
    Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review.
    Golsorkhi M; Koch J; Pedouim F; Frei K; Bondariyan N; Dashtipour K
    Tremor Other Hyperkinet Mov (N Y); 2024; 14():13. PubMed ID: 38497033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia.
    Aggarwal S; Serbin M; Yonan C
    J Comp Eff Res; 2019 Oct; 8(13):1077-1088. PubMed ID: 31464152
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
    Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia.
    Khorassani F; Luther K; Talreja O
    Am J Health Syst Pharm; 2020 Jan; 77(3):167-174. PubMed ID: 31974564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deutetrabenazine in the treatment of tardive dyskinesia.
    Niemann N; Jimenez-Shahed J
    Neurodegener Dis Manag; 2019 Apr; 9(2):59-71. PubMed ID: 30702019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
    Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension Study.
    Hauser RA; Barkay H; Fernandez HH; Jimenez-Shahed J; Factor SA; Gross N; Marinelli L; Gordon MF; Barash S; Finkbeiner S; Chaijale N; Anderson KE
    J Clin Psychopharmacol; 2024 Jul-Aug 01; 44(4):386-396. PubMed ID: 38901008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study.
    Factor SA; Remington G; Comella CL; Correll CU; Burke J; Jimenez R; Liang GS; O'Brien CF
    J Clin Psychiatry; 2017; 78(9):1344-1350. PubMed ID: 29141124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.
    O'Brien CF; Jimenez R; Hauser RA; Factor SA; Burke J; Mandri D; Castro-Gayol JC
    Mov Disord; 2015 Oct; 30(12):1681-7. PubMed ID: 26346941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia.
    Ganz ML; Chavan A; Dhanda R; Serbin M; Yonan C
    J Med Econ; 2021; 24(1):103-113. PubMed ID: 33393412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference.
    Stacy M; Sajatovic M; Kane JM; Cutler AJ; Liang GS; O'Brien CF; Correll CU
    Mov Disord; 2019 Aug; 34(8):1203-1209. PubMed ID: 31234240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.